New data from Janssen presented at the Annual European Congress of Rheumatology EULAR 2019 shows sustained clinical benefit and reduction in severe flares with Stelara ustekinumab in patients with systemic lupus erythematosus SLE

The Janssen Pharmaceutical Companies of Johnson & Johnson presented this week results of two analyses from a Phase 2 study of Stelara ustekinumab in systemic lupus erythematosus SLE. The studies highlight not only the susta...